Drugmaker AbbVie has agreed to license a weight-loss drug currently in development from Gubra for up to about $2.2 billion, ...
Over 30 state attorneys general including in Indiana, Kentucky, and Ohio have urged the Federal Food and Drug Administration ...
A medical device company has secured investment from the owner of the developer of Ozempic and a private equity firm, to ...
AbbVie on Monday jumped into the hot weight-loss space, looking to gain ground on its Big Pharma peers, with a licensing deal ...
Consumers who use telehealth or medical spas to get less expensive, compounded weight loss drugs will need to get their ...
Newser on MSN2d
FDA Change on Ozempic to Shake Up the MarketThe shortage of Ozempic and Wegovy has been declared over by the Food and Drug Administration, a change that suggests higher ...
Nearly one-third of adult employees would change jobs in order to gain coverage. As the demand for GLP-1 weight loss ...
Outsourcing Facilities Association and North American Custom Laboratories allege the FDA removed semaglutide from its ...
New diabetes medications are pressuring Medicare Part D financially as they drive up prescription drug costs amid rising ...
Drug compounders aren’t ready to give up their ability to produce off-brand versions of Novo Nordisk’s weight-loss drug ...
Despite the continued success of GLP-1 drugs Ozempic and Wegovy, Novo Nordisk CEO Lars Fruergaard Jørgensen took a slight pay cut in 2024. He received 57.1 million Danish kroner (DKK) – $8 million – ...
A lawsuit challenges the FDA's decision to remove semaglutide from the shortage list, alleging it was arbitrary and harms ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback